Novartis drug del-desiran misses late-stage trial goal
In short
Novartis said its drug del-desiran failed a late-stage study in myotonic dystrophy type 1.
This is the company's third trial setback in a week, and the report says it adds pressure as Novartis nears a major patent cliff. The story does not say what the next step is for the drug.
What the reporting says
Novartis suffered its third clinical-trial setback in a week after del-desiran failed to meet the main goal of a late-stage study in myotonic dystrophy type 1. The publisher-supplied summary says the drug had been seen as a potential blockbuster and that the result adds pressure on Novartis's pipeline as it approaches a major patent cliff. The report does not state the data details or next company step.
Why it matters
Novartis suffered another clinical-trial setback after del-desiran failed to meet the main goal of a late-stage study in myotonic dystrophy type 1. The summary says this is the company's third such setback in a week and that the result adds pressure on its pipeline as it approaches a major patent cliff. The report does not provide trial numbers, timing, or financial impact.